Strategies for Developing Medical Device Sales in the Ambulatory Surgery Center Market

Driven by population aging and national policies, China’s market for high-value medical consumables has entered a dual phase of rapid growth and domestic substitution of imports. Meanwhile, with technological innovation and enhanced overall competitiveness, Chinese brands are continuously expanding into overseas markets, including Europe and the United States, in search of new growth opportunities and drivers. According to relevant statistical data, the United States, Europe, and Australia remain the primary export destinations for China’s orthopedic implants. Clarivate analysis indicates that, influenced by the pandemic, patient preferences are shifting from traditional inpatient care to outpatient services. In this context, how should medical device companies leverage scientifically driven data evidence and business insights to make timely adjustments, adapt to an ever-changing and fiercely competitive market, and provide relevant support for R&D strategies?

At 14:00 on December 14, Clarivate will host an event themedHow to Develop a Medical Device Sales Strategy for the Ambulatory Surgery Center MarketOnline Live Webinar: Join Ms. Zeng Yali, Senior Consultant at Clarivate’s Life Sciences & Healthcare Division, for an In-Depth Discussion.Welcome to register for the conference!

Key Topics of This Symposium:

1. Variations in Surgical Volume Across Different Service Settings

2. Preferences and Procurement Behaviors of Ambulatory Surgery Centers (ASCs)

3. Growth Trends and Competitive Dynamics in Specific Markets

4. Clarivate’s Integrated Solutions for Medical Devices and In Vitro Diagnostics

Zeng Yali

Clarivate

Life Sciences & Healthcare | Senior Advisor

Graduated from West China University of Medical Sciences, with nearly two decades of experience in the biopharmaceutical industry. Has held positions at multiple biopharmaceutical companies in the United States and China, specializing in global strategic layout, global market access and regulatory affairs, strategic partnerships/project evaluation and licensing-in, supply chain management, and risk control. Has participated in numerous international cooperation projects and possesses extensive experience collaborating with multinational corporations, demonstrating keen analytical and insightful capabilities regarding international market trends.Joined Clarivate in 2018. Recent key industry research initiatives led or contributed to include: *Benchmarking Global Leaders: Outlook for the Future of Chinese Innovative Pharmaceutical Companies*, *Analysis of Global New Drug R&D Trends*, *The Impact of Humira Biosimilars on the U.S. Market*, *Global New Drug R&D Performance and Approval Trends*, *Blue Book on the Internationalization of China’s Pharmaceutical Industry*, *Series of Research Reports on Emerging Market Trends*, *Competitive Landscape and Market Insights for Biosimilars*, *Project Report on the Implementation and Status of ICH Guidelines*, *Focus on Accelerated Review Pathways and Internationalization*, *Discussion on Rapid Approval Mechanisms and Regulatory Flexibility for Medical Products During Public Health Emergencies*, *Research Report on the Progress of COVID-19 Vaccine Development*, and *Practical Discussion on Improving Drug Approval Efficiency in the Context of Regulatory Science Development*. Selected research findings have been invited for publication in journals such as *China Food and Drug Administration*, *China Pharmaceutical News*, *China Pharmaceutical Economy & Trade*, and *Rational Drug Use*.

Scan the QR code to register now